News

Approximately one in 200,000 people in France is diagnosed with narcolepsy every year, according to a study. “This evaluation of population-level data from [national databases] provides a robust estimate of incidence of narcolepsy in France,” the researchers wrote. They also found that people newly diagnosed with narcolepsy accrue…

A protein called UNC5C that’s involved in nervous system development may serve as a blood-based biomarker to diagnose and/or track type 1 narcolepsy (NT1), a new exploratory study reports. After examining hundreds of proteins and gene activity in blood samples, researchers in Sweden and Finland discovered that UNC5C protein…

Two features of rapid eye movement (REM) sleep, the sleep stage characterized by high brain activity and vivid dreaming, may help distinguish people with narcolepsy from those with other conditions that cause excessive daytime sleepiness. That’s according to a study that measured aspects of REM sleep using a multiple…

While people with narcolepsy often face challenges at school and at work, they can be successful with support, understanding, and appropriate accommodations, a study showed. “The results underscore the importance of implementing … adaptive strategies and the need for a supportive environment” to allow people with narcolepsy to thrive…

New survey findings highlight that narcolepsy can affect much more than daytime alertness, with many Canadians reporting lengthy delays in diagnosis and a substantial impact on their daily lives. That burden was reflected in quality-of-life ratings, with 68% of respondents scoring narcolepsy impact between eight and 10 on a…

Advocates around the globe are marking World Narcolepsy Day today with campaigns to correct common misconceptions about the condition, reduce delays in diagnosis, and support the estimated three million people living with narcolepsy worldwide. “This day is dedicated to raising awareness of narcolepsy on a global scale,” Project…

Japan’s Ministry of Health, Labour and Welfare has approved Wakix (pitolisant), a once-daily oral treatment, for narcolepsy types 1 and 2. Wakix is used to treat excessive daytime sleepiness (EDS) and cataplexy in people with narcolepsy. The country also approved the first-in-class therapy for EDS associated with obstructive…

Alkermes is now accepting research grant applications focused on narcolepsy and other neurological conditions. The biopharmaceutical company announced that it will accept initial letters of intent for its annual Alkermes Pathways Research Awards program through Oct. 16. The initiative provides up…

A new review, by an international team of scientists, confirms what was found in two large, late-stage clinical trials: The now-approved narcolepsy drug Orzeyful (oveporexton) worked significantly better than a placebo in reducing measures of sleepiness and easing a wide range of other symptoms in people with…

A wearable device using an algorithm may offer an objective way to track daytime napping and excessive daytime sleepiness (EDS) in people with type 1 narcolepsy (NT1), a study found. The “highly sensitive and specific algorithm” detected substantially more frequent and longer daytime sleep in people with NT1 than in…